Dashboard › Demo Universe › Halcyon Medical Devices

Halcyon Medical Devices · HLCN

DEMO DATAUNDERWRITING ASSUMPTIONHOLD

Financial statements DEMO DATA

$MFY2022AFY2023AFY2024AFY2025A
Revenue$1.2B$1.3B$1.3B$1.4B
% growth6.8%5.6%5.3%
Direct costs / COGS$407.1M$428.4M$445.5M$476.0M
Gross profit (NOI for real estate)$772.9M$831.6M$884.5M$924.0M
% margin65.5%66.0%66.5%66.0%
Operating expenses (cash, adjusted)$495.6M$529.2M$558.6M$588.0M
EBITDA (company-adjusted basis)$277.3M$302.4M$325.8M$336.0M
% margin23.5%24.0%24.5%24.0%
D&A$53.1M$56.7M$59.8M$63.0M
Share-based compensation$0.0M$0.0M$0.0M$0.0M
EBIT$224.2M$245.7M$266.0M$273.0M
Interest expense$50.2M$53.2M$56.1M$59.1M
EBT$174.0M$192.5M$209.9M$213.9M
Taxes$43.5M$48.1M$52.5M$53.5M
Net income (model basis)$130.5M$144.4M$157.4M$160.4M
Capex$47.2M$50.4M$53.2M$56.0M
Working capital & other cash items$6.7M$9.6M$8.4M$8.4M
Free cash flow$129.6M$141.1M$155.6M$159.0M

Historical columns are fictional demo inputs. Projections flow from the selected scenario’s assumptions (Scenarios tab): interest accrues on beginning balances by tranche; floating tranches use MAX(SOFR, floor) + spread + scenario shock; PIK accrues to principal. FCF = net income + D&A + SBC + PIK − capex − ΔNWC / other. Impairments, restructuring and other one-offs are excluded from EBITDA and net income and sit in the cash plug.

Sources & data lineage (3)
SourceDocumentData typePeriodAccessionDoc dateRetrievedClass
CreditIQ demo datasetHalcyon Medical Devices — illustrative financial statements FY2022–FY2025Income statement / cash flowFY2022–FY2025—2026-03-312026-03-31DEMO DATA
CreditIQ demo datasetHalcyon Medical Devices — illustrative capital structure & covenantsDebt scheduleAs of 2026-03-31—2026-03-312026-03-31DEMO DATA
CreditIQ demo datasetIllustrative indicative bid marks (% of par)Market price2026-03-31—2026-03-312026-03-31DEMO DATA